| About the author: |
J. N. Akhundova, M. F. Amirova |
| Heading |
CLINICAL MEDICINE |
| Type of article |
Scentific article |
| Annotation |
In this study, breast cancer patients aged 24–75 (53.9±0.8) were fully examined, and breast cancer receptor status immunohistochemical analysis was made by Allred scale. Lymph node’s size, shape, structure were recorded according to an ultrasound exam on “LOGIQ C5-Premium” (2012). The statistical analysis of obtained results was carried out using SPSS-26 software package. The sensitivity and specificity of indicators studied were shaped by ROC statistical analysis. The study results showed a significant association of subtypes as well as receptor expression with tumor metastasis to axillary lymph nodes. We found that HER2+ is the most aggressive breast cancer subtype in terms of tumor malignancy and morphological changes in axillary lymph nodes, leading to complete destruction of the node cortex structure, and therefore axillary lymph nodes in this subtype must be removed during surgical resection of primary cancer foci without fail. |
| Tags |
lymph nodes,breast cancer,cancer subtypes,lymph cortex,receptors |
| Bibliography |
- Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M. et al. Current and future burden of breast cancer: Global statistics for 2020 and 2040. Breast. 2022 Dec; 66:15–23. doi: 10.1016/j.breast.2022.08.010.
- Cabıoğlu N, Karanlık H, Yıldırım N, Müslümanoğlu M, Çakmak G Karadeniz, Can DT. et al. Favorable outcome with sentinel lymph node biopsy alone after neoadjuvant chemotherapy in clinically node positive breast cancer at diagnosis: Turkish Multicentric NEOSENTI-TURK MF-18-02-study. Eur J Surg Oncol. 2021;47: 2506–2514. doi: 10.1016/j.ejso.2021.06.024.
- Cho N. Imaging features of breast cancer molecular subtypes: state of the art. Journal of Pathology and Translational Medicine 2021; 55: 16–25. doi:10.4132/jptm.2020.09.03.
- Chung HL, Le-Petross HT, Leung JWT. Imaging Updates to Breast Cancer Lymph Node Management. Radiographics. 2021 Sep-Oct;41(5):1283–1299. doi: 10.1148/rg.2021210053.
- Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, Senn HJ; Panel members. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013 Sep;24(9):2206–23. doi: 10.1093/annonc/mdt303.
- He ZY, Wu SG, Yang Q, Sun JY, Li FY, Lin Q, Lin HX. Breast Cancer Subtype is Associated With Axillary Lymph Node Metastasis: A Retrospective Cohort Study. Medicine (Baltimore). 2015 Dec;94(48): e2213. doi: 10.1097/MD.0000000000002213.
- Iqbal N, Iqbal N. Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications. Mol Biol Int. 2014:852748. doi: 10.1155/2014/852748.
- D. Kustic, F. Lovasic, I. Belac-Lovasic, M. Avirovic, A. Ruzic, S. P. Majnaric. Impact of HER2 on axillary metastasis in breast carcinoma – Rev Med Chile 2019; 147: 557–567.
- Morkavuk ŞB, Güner M, Çulcu S, Eroğlu A, Bayar S, Ünal AE. Relationship between lymphovascular invasion and molecular subtypes in invasive breast cancer. Int J Clin Pract. 2021 Apr;75(4):e13897. doi: 10.1111/ijcp.13897.
- Nicolini A, Ferrari P, Duffy MJ. Prognostic and predictive biomarkers in breast cancer: Past, present and future. Semin Cancer Biol. 2018;52(1):56–73. doi: 10.1016/j. semcancer.2017.08.010.
- Shaath H, Elango R, Alajez NM. Molecular Classification of Breast Cancer Utilizing Long Non-Coding RNA (lncRNA) Transcriptomes Identifies Novel Diagnostic lncRNA Panel for Triple-Negative Breast Cancer. Cancers. 2021;13(21):5350. doi: 10.3390/cancers13215350.
- Torrisi R, Marrazzo E, Agostinetto E, De Sanctis R, Losurdo A, Masci G. Neoadjuvant chemotherapy in hormone receptor-positive/HER2-negative early breast cancer: when, why and what? Crit Rev Oncol Hematol. 2021;160: doi: 10.1016/j.critrevonc.2021.103280.
|
| Publication of the article |
«World of Medicine and Biology» №4(90), 2024 year, 015-019 pages, index UDK 616-006 |
| DOI |
10.26724/2079-8334-2024-4-90-15-19 |
